Browse UBQLN1

Summary
SymbolUBQLN1
Nameubiquilin 1
Aliases PLIC-1; XDRP1; DA41; UBQN; hPLIC-1; protein linking IAP with cytoskeleton 1; Ubiquilin-1
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Endoplasmic reticulum Cytoplasmic vesicle, autophagosome Cell membrane Note=Detected in neuronal processes and at synapses (By similarity). Recruited to the ER during ER-associated protein degradation (ERAD) (PubMed:19822669). Isoform 1 and isoform 3 colocalize with PSEN1 in the cell membrane and in cytoplasmic juxtanuclear structures called aggresomes (PubMed:21143716). Colocalizes with ORAI1 and TICAM1 in the autophagosome (PubMed:23307288, PubMed:21695056). Colocalizes with EPS15 and HGS in ubiquitin-rich cytoplasmic aggregates that are not endocytic compartments and with EPS15 also in aggresomes (PubMed:16159959).
Domain PF00627 UBA/TS-N domain
PF00240 Ubiquitin family
Function

Plays an important role in the regulation of different protein degradation mechanisms and pathways including ubiquitin-proteasome system (UPS), autophagy and endoplasmic reticulum-associated protein degradation (ERAD) pathway. Mediates the proteasomal targeting of misfolded or accumulated proteins for degradation by binding (via UBA domain) to their polyubiquitin chains and by interacting (via ubiquitin-like domain) with the subunits of the proteasome (PubMed:15147878). Plays a role in the ERAD pathway via its interaction with ER-localized proteins UBXN4, VCP and HERPUD1 and may form a link between the polyubiquitinated ERAD substrates and the proteasome (PubMed:19822669, PubMed:18307982). Isoform 1, isoform 2 and isoform 3 play a role in unfolded protein response (UPR) by attenuating the induction of UPR-inducible genes, DDTI3/CHOP, HSPA5 and PDIA2 during ER stress (PubMed:18953672). Involved in the regulation of macroautophagy and autophagosome formation; required for maturation of autophagy-related protein LC3 from the cytosolic form LC3-I to the membrane-bound form LC3-II and may assist in the maturation of autophagosomes to autolysosomes by mediating autophagosome-lysosome fusion (PubMed:19148225, PubMed:20529957, PubMed:23459205). Negatively regulates the TICAM1/TRIF-dependent toll-like receptor signaling pathway by decreasing the abundance of TICAM1 via the autophagic pathway (PubMed:21695056). Isoform 1 and isoform 3 play a key role in the regulation of the levels of PSEN1 by targeting its accumulation to aggresomes which may then be removed from cells by autophagocytosis (PubMed:21143716). Promotes the ubiquitination and lysosomal degradation of ORAI1, consequently downregulating the ORAI1-mediated Ca2+ mobilization (PubMed:23307288). Suppresses the maturation and proteasomal degradation of amyloid beta A4 protein (A4) by stimulating the lysine 63 (K63)-linked polyubiquitination. Delays the maturation of A4 by sequestering it in the Golgi apparatus and preventing its transport to the cell surface for subsequent processing (By similarity).

> Gene Ontology
 
Biological Process GO:0000045 autophagosome assembly
GO:0001666 response to hypoxia
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002683 negative regulation of immune system process
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0006816 calcium ion transport
GO:0006914 autophagy
GO:0006979 response to oxidative stress
GO:0007033 vacuole organization
GO:0008631 intrinsic apoptotic signaling pathway in response to oxidative stress
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010498 proteasomal protein catabolic process
GO:0010959 regulation of metal ion transport
GO:0016236 macroautophagy
GO:0022898 regulation of transmembrane transporter activity
GO:0030433 ER-associated ubiquitin-dependent protein catabolic process
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031349 positive regulation of defense response
GO:0031396 regulation of protein ubiquitination
GO:0031398 positive regulation of protein ubiquitination
GO:0032409 regulation of transporter activity
GO:0032410 negative regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0032413 negative regulation of ion transmembrane transporter activity
GO:0032434 regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0034121 regulation of toll-like receptor signaling pathway
GO:0034122 negative regulation of toll-like receptor signaling pathway
GO:0034138 toll-like receptor 3 signaling pathway
GO:0034139 regulation of toll-like receptor 3 signaling pathway
GO:0034140 negative regulation of toll-like receptor 3 signaling pathway
GO:0034599 cellular response to oxidative stress
GO:0034762 regulation of transmembrane transport
GO:0034763 negative regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034766 negative regulation of ion transmembrane transport
GO:0034976 response to endoplasmic reticulum stress
GO:0035973 aggrephagy
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0036473 cell death in response to oxidative stress
GO:0036503 ERAD pathway
GO:0042176 regulation of protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043271 negative regulation of ion transport
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045732 positive regulation of protein catabolic process
GO:0045862 positive regulation of proteolysis
GO:0048284 organelle fusion
GO:0051051 negative regulation of transport
GO:0051924 regulation of calcium ion transport
GO:0051926 negative regulation of calcium ion transport
GO:0061136 regulation of proteasomal protein catabolic process
GO:0070482 response to oxygen levels
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0072511 divalent inorganic cation transport
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097352 autophagosome maturation
GO:0097576 vacuole fusion
GO:1900407 regulation of cellular response to oxidative stress
GO:1901019 regulation of calcium ion transmembrane transporter activity
GO:1901020 negative regulation of calcium ion transmembrane transporter activity
GO:1901339 regulation of store-operated calcium channel activity
GO:1901340 negative regulation of store-operated calcium channel activity
GO:1901800 positive regulation of proteasomal protein catabolic process
GO:1902175 regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
GO:1902882 regulation of response to oxidative stress
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903052 positive regulation of proteolysis involved in cellular protein catabolic process
GO:1903069 regulation of ER-associated ubiquitin-dependent protein catabolic process
GO:1903071 positive regulation of ER-associated ubiquitin-dependent protein catabolic process
GO:1903169 regulation of calcium ion transmembrane transport
GO:1903170 negative regulation of calcium ion transmembrane transport
GO:1903201 regulation of oxidative stress-induced cell death
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
GO:1903362 regulation of cellular protein catabolic process
GO:1903364 positive regulation of cellular protein catabolic process
GO:1904062 regulation of cation transmembrane transport
GO:1904063 negative regulation of cation transmembrane transport
GO:1904292 regulation of ERAD pathway
GO:1904294 positive regulation of ERAD pathway
GO:1905037 autophagosome organization
GO:2001233 regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001257 regulation of cation channel activity
GO:2001258 negative regulation of cation channel activity
Molecular Function GO:0031593 polyubiquitin binding
GO:0032182 ubiquitin-like protein binding
GO:0043130 ubiquitin binding
Cellular Component GO:0000502 proteasome complex
GO:0005776 autophagosome
GO:0016234 inclusion body
GO:0016235 aggresome
GO:1905368 peptidase complex
GO:1905369 endopeptidase complex
> KEGG and Reactome Pathway
 
KEGG hsa04141 Protein processing in endoplasmic reticulum
Reactome R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-199991: Membrane Trafficking
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolUBQLN1
Nameubiquilin 1
Aliases PLIC-1; XDRP1; DA41; UBQN; hPLIC-1; protein linking IAP with cytoskeleton 1; Ubiquilin-1
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between UBQLN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolUBQLN1
Nameubiquilin 1
Aliases PLIC-1; XDRP1; DA41; UBQN; hPLIC-1; protein linking IAP with cytoskeleton 1; Ubiquilin-1
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of UBQLN1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 5.13; FDR: 0.002 Resistant to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 4.35; FDR: 0.013 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolUBQLN1
Nameubiquilin 1
Aliases PLIC-1; XDRP1; DA41; UBQN; hPLIC-1; protein linking IAP with cytoskeleton 1; Ubiquilin-1
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of UBQLN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1370.598
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3340.891
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0080.997
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2690.498
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0190.993
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6410.827
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1490.75
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0630.976
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2440.916
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3140.827
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7910.717
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0960.0809
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of UBQLN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUBQLN1
Nameubiquilin 1
Aliases PLIC-1; XDRP1; DA41; UBQN; hPLIC-1; protein linking IAP with cytoskeleton 1; Ubiquilin-1
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UBQLN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUBQLN1
Nameubiquilin 1
Aliases PLIC-1; XDRP1; DA41; UBQN; hPLIC-1; protein linking IAP with cytoskeleton 1; Ubiquilin-1
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UBQLN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UBQLN1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUBQLN1
Nameubiquilin 1
Aliases PLIC-1; XDRP1; DA41; UBQN; hPLIC-1; protein linking IAP with cytoskeleton 1; Ubiquilin-1
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UBQLN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUBQLN1
Nameubiquilin 1
Aliases PLIC-1; XDRP1; DA41; UBQN; hPLIC-1; protein linking IAP with cytoskeleton 1; Ubiquilin-1
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of UBQLN1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUBQLN1
Nameubiquilin 1
Aliases PLIC-1; XDRP1; DA41; UBQN; hPLIC-1; protein linking IAP with cytoskeleton 1; Ubiquilin-1
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between UBQLN1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUBQLN1
Nameubiquilin 1
Aliases PLIC-1; XDRP1; DA41; UBQN; hPLIC-1; protein linking IAP with cytoskeleton 1; Ubiquilin-1
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting UBQLN1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.